论文部分内容阅读
据Inpharma 1995.11.4.P8报道,研究者在开发一类新的抗菌剂,噁唑酮类,为医生提供了一些能战胜细菌对标准剂,如青霉素、头孢菌素和万古霉素耐药菌逐渐上升的问题。重要的是噁唑酮的体外活性谱复盖葡萄球菌、肠球菌、链球菌、肺炎球菌和结核分支杆菌,包括耐其它抗菌剂的菌株。1995年9月在美国圣弗朗西斯科召开的第35次抗微生物剂和化学治疗剂方面的国际科学讨论会(ICAAC)上展示了临床前和早期临床试验中的这些药物的性质。
According to Inpharma, Nov. 4, 1995, P. 8 reports that researchers in the development of a new class of antibacterial agents, oxazolones, provide physicians with the ability to overcome some bacterial resistance to standard agents such as penicillins, cephalosporins, and vancomycin- Gradually rising problems. Importantly, the in vitro activity profile of oxazolone covers staphylococci, enterococci, streptococci, pneumococci and M. tuberculosis, including those resistant to other antibacterial agents. The nature of these drugs in preclinical and early clinical trials was demonstrated at the 35th International Symposium on Antibiocides and Chemotherapeutics (ICAAC) held in September 1995 in San Francisco, USA.